Copyright © Inderes 2011 - present. All rights reserved.
Log in to your Inderes Free account to see all free content on this page.
Create account

NextCell Pharma

1.28 SEK

+44.31 %

Less than 1K followers

NXTCL

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

+44.31 %
+75.10 %
+88.79 %
+44.31 %
+24.03 %
-46.67 %
-77.46 %
-90.12 %
-42.12 %

NextCell Pharma operates in the healthcare sector. The company develops stem cell products that are mainly used in the treatment of autoimmune diabetes and kidney transplantation. A large part of the work consists of stem cell research where the company develops drug candidates that will facilitate and increase acceptance in organ transplantation. In addition, the company owns a stem cell bank. The company was founded in 2014 and has its headquarters in Huddinge.

Read more
Market cap
142.58M SEK
Turnover
6.17M SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
28.5.
2026

Interim report Q1'26

27.8.
2026

Interim report Q2'26

26.11.
2026

Interim report Q3'26

ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.